facebook
twitter
instagram
linkedin
pinterest
youtube
magnify
user
heart
arrow-right
chevron-up
chevron-left
chevron-right
chevron-down
Javascript must be enabled for the correct page display
Skip to Content
User icon
NEALS Member Portal
Search Trials
Contact a Specialist
Community Education Webinars
Heart icon
Donate
Search icon
Search
Search icon
Search
People Living with ALS
About ALS and Motor Neuron Disease
Community Education Webinars
ALS Clinical Research Learning Institute®
Online ALS Resources
Additional Resources & Information
Get Involved
ALS Researchers
Become a NEALS Member
NEALS Clinical Trial Capabilities
2025 Annual NEALS Meeting
NEALS Single Institutional Review Board (cIRB)
NEALS Sample Repository
Historical Trial Data
Post an ALS Clinical Trial
Upcoming Research Opportunities
Collaborate with NEALS
NEALS Scientific Advisory Board
NEALS Affiliated Trials
PEACe Committee
ALS Research & Trials
ALS Clinical Research
Search for a Trial
Expanded Access
Trial News & Events
About
Our Mission
Our Structure
NEALS Member Sites
Contact Us
Join Our Email List
Search Trials
Contact a Specialist
Community Education Webinars
Search form
Search:
Search icon
Search close
HOME
ALS Trials
Trial News & Events
"Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS," published by Amylyx Pharmaceuticals
June 13, 2022
